Prelude Therapeutics Inc PRLD:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 04/17/24 EDT
3.44UNCH (UNCH)
Volume
111,799
52 week range
1.66 - 8.44
Loading...
  • Open4.16
  • Day High4.18
  • Day Low3.42
  • Prev Close3.44
  • 52 Week High8.44
  • 52 Week High Date04/18/23
  • 52 Week Low1.66
  • 52 Week Low Date11/01/23

Key Stats

  • Market Cap188.927M
  • Shares Out54.92M
  • 10 Day Average Volume0.04M
  • Dividend-
  • Dividend Yield-
  • Beta1.51
  • YTD % Change-19.44

KEY STATS

  • Open4.16
  • Day High4.18
  • Day Low3.42
  • Prev Close3.44
  • 52 Week High8.44
  • 52 Week High Date04/18/23
  • 52 Week Low1.66
  • 52 Week Low Date11/01/23
  • Market Cap188.927M
  • Shares Out54.92M
  • 10 Day Average Volume0.04M
  • Dividend-
  • Dividend Yield-
  • Beta1.51
  • YTD % Change-19.44

RATIOS/PROFITABILITY

  • EPS (TTM)-2.05
  • P/E (TTM)-1.68
  • Fwd P/E (NTM)-1.72
  • EBITDA (TTM)-131.108M
  • ROE (TTM)-56.33%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date05/06/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Prelude Therapeutics Inc

 

Profile

MORE
Prelude Therapeutics Incorporated is a clinical-stage fully integrated oncology company built on a foundation of drug discovery to deliver novel precision cancer medicines to underserved patients. It has developed a diverse pipeline consisting of multiple distinct programs: kinases, targeted protein degraders, and precision antibody drug conjugates. Its product candidates include PRT3789, PRT2527 and PRT3645. PRT3789 is a highly selective degrader of SMARCA2 protein, which...
Paul Friedman M.D.
Independent Chairman of the Board
Krishna Vaddi Ph.D.
Chief Executive Officer, Founder, Director
Jane Huang M.D.
President, Chief Medical Officer
Bryant Lim J.D.
Interim Chief Financial Officer, Chief Legal Officer and Corporate Secretary
Andrew Combs Ph.D.
Executive Vice President, Head of Chemistry
Address
175 Innovation Boulevard
Wilmington, DE
19805
United States

Top Peers

SYMBOLLASTCHG%CHG
ACRV
Acrivon Therapeutics Inc
10.54UNCHUNCH
NAUT
Nautilus Biotechnology Inc
2.34UNCHUNCH
OPT
Opthea Ltd
3.40UNCHUNCH
AVIR
Atea Pharmaceuticals Inc
3.70UNCHUNCH
INZY
Inozyme Pharma Inc
4.58UNCHUNCH